

Supplemental Approvals

Generic Name (Trade Name—Company)

August 30, 2018

Lenvatinib

(Lenvima—Eisai Inc.)

Lenvatinib has new indication for treatment of unresectable hepatocellular carcinoma

Uses/Notes

FDA has approved [lenvatinib](#) capsules for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Approval was based on an international, multicenter, randomized, open-label, noninferiority trial conducted in 954 patients with previously untreated, metastatic or unresectable HCC.

Patients were randomized (1:1) to receive lenvatinib (12 mg orally once daily for patients with a baseline body weight of \geq 60 kg and 8 mg orally once daily for patients with a baseline body weight of

Source URL:

<http://www.aphanet.org/supplemental-approvals/lenvatinib-has-new-indication-treatment-unresectable-hepatocellular-carcinoma>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.